Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 5:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 6,731 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Medication Management Clear all
Completed Phase 3 Interventional Results available

Study to Assess the Tolerability and the Safety of the Transition From Inhaled Treprostinil to Oral Selexipag in Patients With Pulmonary Arterial Hypertension

NCT02471183
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Selexipag
Drug
Lead sponsor
Actelion
Industry
Eligibility
18 Years to 75 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
15
States / cities
La Jolla, California • San Francisco, California • Torrance, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 20, 2026, 5:54 AM EDT
Completed Not applicable Interventional Results available

Practical Telemedicine to Improve Control and Engagement for Veterans With Clinic-Refractory Diabetes Mellitus

NCT03520413
View directory record Official record
Conditions
Telemedicine
Interventions
PRACTICE-DM, Standard VA Home Telehealth
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 70 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
2
States / cities
Durham, North Carolina • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Oct 20, 2026, 5:54 AM EDT
Recruiting Phase 3 Interventional

Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)

NCT07654361
View directory record Official record
Conditions
Obesity, Overweight, Chronic Weight Management
Interventions
Aleniglipron, Placebo
Drug
Lead sponsor
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Industry
Eligibility
18 Years to 79 Years
Enrollment
3,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
71
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sun City West, Arizona + 64 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 20, 2026, 5:54 AM EDT
Completed Not applicable Interventional Results available

Positive Minds Strong Bodies Implementation

NCT04545593
View directory record Official record
Conditions
Depression, Anxiety, Physical Disability
Interventions
Positive Minds Strong Bodies Enhanced, Enhanced Usual Care
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
60 Years and older
Enrollment
427 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 20, 2026, 5:54 AM EDT
Not listed No phase listed Observational

Ocular-vestibular Biomarker Identification for ADHD

NCT04504890
View directory record Official record
Conditions
ADHD - Combined Type, ADHD, ADHD Predominantly Inattentive Type, ADHD, Predominantly Hyperactive - Impulsive
Interventions
EYE-SYNC
Device
Lead sponsor
Sync-Think, Inc.
Industry
Eligibility
6 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
San Carlos, California
Source: ClinicalTrials.gov public record
Updated Oct 23, 2020 · Synced Oct 20, 2026, 5:54 AM EDT
Recruiting Phase 3 Interventional

D2 - Isa-Iber-VD Induction, Followed by Risk & Response Adapted Consolidation & Maintenance, in Transplant-Eligible NDMM

NCT07624513
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Isatuximab, Iberdomide, Bortezomib (B), Dexamethasone, Melphalan, Linvoseltamab, On Body Delivery System (OBDS)
Drug · Device
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
720 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2038
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 20, 2026, 5:54 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Meaningful Use of Technology to Improve Health Care Delivery

NCT01641380
View directory record Official record
Conditions
Contraceptive Behavior
Interventions
Text Messaging Intervention
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
13 Years to 21 Years · Female only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 2, 2021 · Synced Oct 20, 2026, 5:54 AM EDT
Completed Phase 1 Interventional

Interaction Study to Assess the Pharmacokinetic Interaction of Oral Administration of Rifapentine on ATRIPLA™ in HIV Patients

NCT01690403
View directory record Official record
Conditions
Tuberculosis
Interventions
rifapentine (M000473), EFZ EMT TDF
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 55 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Feb 27, 2015 · Synced Oct 20, 2026, 5:54 AM EDT
Enrolling by invitation Not applicable Interventional

Addressing Psychosocial Comorbidities in HIV Treatment and Prevention 2b

NCT05352061
View directory record Official record
Conditions
Medication Adherence, Mental Health Issue
Interventions
CBT for Syndemics and Adherence Factors
Behavioral
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 20, 2026, 5:54 AM EDT
Terminated Phase 3 Interventional

Study of NGX-4010 for Treatment of Painful HIV-Associated Neuropathy

NCT00085761
View directory record Official record
Conditions
HIV Infections, Peripheral Nervous System Diseases, Pain
Interventions
Capsaicin Dermal Patch
Drug
Lead sponsor
NeurogesX
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
Sarasota, Florida • Annandale, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 6, 2008 · Synced Oct 20, 2026, 5:54 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate How the Study Drug Moves Through the Body, Adverse Events, and How the Body Tolerates ABBV-547 Injections

NCT07232004
View directory record Official record
Conditions
Healthy Volunteer, Psoriasis
Interventions
ABBV-547, ABBV-547 Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 70 Years
Enrollment
142 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
18
States / cities
Birmingham, Alabama • Bryant, Arkansas • Anaheim, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 20, 2026, 5:54 AM EDT
Completed Phase 1 Interventional Results available

Effect of Bismuth Subsalicylate on the Gut Microbiome and Host Response in Healthy Adults

NCT05930197
View directory record Official record
Conditions
Healthy Adults
Interventions
Bismuth subsalicylate
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Oct 20, 2026, 5:54 AM EDT
Completed Not applicable Interventional Results available

Hospital to Home Outcomes

NCT02081846
View directory record Official record
Conditions
Focus: Hospitalized Patients
Interventions
Nurse Home Visit, Standard of Care
Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Up to 18 Years
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Oct 20, 2026, 5:54 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Crossover Trials Which Assessed Consumption of Slowly Digestible Carbohydrates for 21 Days on Gastric Emptying Rates

NCT05430061
View directory record Official record
Conditions
Obesity, Diabetes
Interventions
slowly digestible carbohydrate
Dietary Supplement
Lead sponsor
Purdue University
Other
Eligibility
18 Years to 50 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
West Lafayette, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 24, 2022 · Synced Oct 20, 2026, 5:54 AM EDT
Completed Phase 3 Interventional Results available

ACTIV-6: COVID-19 Study of Repurposed Medications - Arm A (Ivermectin 400)

NCT05736861
View directory record Official record
Conditions
Covid19
Interventions
Ivermectin, Placebo
Drug · Other
Lead sponsor
Susanna Naggie, MD
Other
Eligibility
30 Years and older
Enrollment
1,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
87
States / cities
Gilbert, Arizona • Mesa, Arizona • Peoria, Arizona + 75 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2023 · Synced Oct 20, 2026, 5:54 AM EDT
Completed No phase listed Observational Results available

Influenza Resistance Information Study

NCT00884117
View directory record Official record
Conditions
Influenza
Interventions
Oseltamivir
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
Not listed
Enrollment
4,561 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 19, 2016 · Synced Oct 20, 2026, 5:54 AM EDT
Active, not recruiting Not applicable Interventional

A Study of the Use of Text Message Reminders to Take Palbociclib

NCT04216576
View directory record Official record
Conditions
Breast Cancer
Interventions
Paper Drug Diary, OhMD APP
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 20, 2026, 5:54 AM EDT
Completed Not applicable Interventional

The Addition of Indinavir to Anti-HIV Treatment in HIV-Infected Patients

NCT00000861
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
16 Years and older
Enrollment
1,900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1997
U.S. locations
14
States / cities
San Francisco, California • Denver, Colorado • Washington D.C., District of Columbia + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Oct 20, 2026, 5:54 AM EDT
Completed No phase listed Observational

Effect of Complementary and Alternative Medicine on Pain Among Inpatients

NCT02190240
View directory record Official record
Conditions
Pain
Interventions
Not listed
Lead sponsor
Allina Health System
Other
Eligibility
18 Years and older
Enrollment
4,422 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 10, 2017 · Synced Oct 20, 2026, 5:54 AM EDT
Terminated Phase 3 Interventional Results available

Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual Chemotherapy Treatment (Cisplatin or Carboplatin With Gemcitabine) for Recurrent or Metastatic Nasopharyngeal Cancer

NCT04458909
View directory record Official record
Conditions
Metastatic Nasopharyngeal Carcinoma, Metastatic Nasopharyngeal Keratinizing Squamous Cell Carcinoma, Metastatic Nasopharyngeal Nonkeratinizing Carcinoma, Metastatic Nasopharyngeal Undifferentiated Carcinoma, Nasopharyngeal Nonkeratinizing Carcinoma, Recurrent Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Keratinizing Squamous Cell Carcinoma, Recurrent Nasopharyngeal Undifferentiated Carcinoma, Stage IV Nasopharyngeal Carcinoma AJCC v8, Stage IVA Nasopharyngeal Carcinoma AJCC v8, Stage IVB Nasopharyngeal Carcinoma AJCC v8
Interventions
Carboplatin, Cisplatin, Gemcitabine, Nivolumab, Questionnaire Administration
Drug · Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
322
States / cities
Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 204 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2025 · Synced Oct 20, 2026, 5:54 AM EDT
Completed Not applicable Interventional

Comparative Effectiveness of Two Tobacco Cessation Interventions for Employees of Partners HealthCare, Inc.

NCT02601521
View directory record Official record
Conditions
Smoking Cessation, Tobacco Use Disorder
Interventions
Internal tobacco coach, External tobacco coach
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 24, 2021 · Synced Oct 20, 2026, 5:54 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

COVID-19-Related Opioid Treatment Policy Evaluation

NCT05028998
View directory record Official record
Conditions
Opioid-use Disorder, Alcohol Use Disorder
Interventions
Not listed
Lead sponsor
Boston VA Research Institute, Inc.
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 1, 2023 · Synced Oct 20, 2026, 5:54 AM EDT
Active, not recruiting Not applicable Interventional

Pain Self-Management and Treatment Engagement for Patients Taking Opioids

NCT06855732
View directory record Official record
Conditions
Chronic Pain, Opioid Use Disorder, Opioid Misuse and Addiction
Interventions
Usual Care, Pain Self-Management
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
17
States / cities
Baltimore, Maryland • Allison Park, Pennsylvania • Blawnox, Pennsylvania + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 20, 2026, 5:54 AM EDT
Active, not recruiting Phase 2 Interventional

Bladder Directed vs. Pelvic Floor Therapy in IC/BPS

NCT02870738
View directory record Official record
Conditions
Cystitis, Interstitial, Painful Bladder Syndrome
Interventions
Pelvic Floor Physical Therapy, Bladder Instillations
Procedure · Drug
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years to 85 Years · Female only
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 20, 2026, 5:54 AM EDT